Ontario expands use of biosimilar drug treatments

Visibility360, PDF version to share

By Susan Yellin | Dec. 26, 2022, 9:53 a.m.

Flash | Regulation | Medication

Photo: Unsplash | Laurynas Mereckas

Ontario Drug Benefit recipients who are on an originator biologic will begin to transition to a Health Canada approved biosimilar version of the drug at the end of March.

This article is reserved to PRO Level subscribers

Discover the PRO Level

The most popular in Health

Drug plan sponsors encouraged to set up usage guardrails for new therapies

Women over 65 less likely than men to visit medical specialists for non-emergencies

Isolation grows among workers under 40

Make your business shine with Visibility360!

Get a PDF version to share in your networks.

I'm interested

Headlines

Insurers pushing their limits in accelerated underwriting

National Flood Insurance Program promised again in budget

Embracing artificial intelligence is crucial for industry

Related topics …

Flash

Insurers pushing their limits in accelerated underwriting

Embracing artificial intelligence is crucial for industry

BrokerLink closes three transactions

Six out of ten workers not performing to their full potential

Regulation

National Flood Insurance Program promised again in budget

Mutual fund rep fined close to $1.7-million

Insurers likely to benefit from adding obesity drugs to benefits coverage

Sanctions for pre-signed forms levied against former Fredericton rep

Medication

Drug plan sponsors encouraged to set up usage guardrails for new therapies

Employee health and wellness metrics decline

Women over 65 less likely than men to visit medical specialists for non-emergencies

One-third of younger adults report using cannabis in the past year